Search results
Results From The WOW.Com Content Network
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter . [ 4 ]
In the same year Switzerland was the second largest exporter of packaged medicine in the world, with about 11% of the global total, worth $36.5 billion. [3] Switzerland is home to many pharmaceutical companies, including very large groups, such as Novartis and Hoffmann-La Roche. In 2013, 41 life science companies had their international ...
The Health Valley covers the Western Switzerland region, where the life sciences sector extends from Geneva to Bern, including the seven cantons of Bern, Fribourg, Geneva, Jura, Neuchâtel, Valais and Vaud. This cluster presents a critical mass of 1,000 companies, research centers and innovation support structures, representing today more than ...
Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise ...
(Reuters) -Edwards Lifesciences on Monday said it has agreed to sell its critical care products unit to Becton Dickinson in an all-cash deal valued at $4.2 billion to sharpen focus on its heart ...
On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:EW) detailed its strategy for sustained long-term growth and innovations in structural heart therapies.
Life Sciences Switzerland (LS2) is the Swiss federation of scientific societies for life sciences. It was formerly known as the Union of the Swiss Societies for Experimental Biology (USGEB). [1] [2] It was founded in 1969, with the founding meeting taking place in Bern, Switzerland.
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson.It later moved its headquarters to New Jersey. In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick ...